Incyte (INCY) announced topline results from its Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib, an ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

The next four patients will receive a higher dose of LyGenesis's cell therapy to grow functioning liver tissue in patients with end stage liver disease The DSMB reviewed the safety, tolerability ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

An influential group of MPs has warned that HS2 is an example of “how not to ... in the western suburbs and at Birmingham Airport. Phase 2A: To extend the line from Fradley in the West Midlands ...

Metsera has shared positive topline results from the Phase 2a trial, reporting up to 11.3% mean placebo-adjusted weight loss at 12 weeks, with no evidence of a plateau. These results demonstrate the ...

There’s a large delta between $28 billion and $53.8 billion. According to the report, where the final tally falls will be determined by the rapidity of the process and whether a few key best ...

The UK’s High Speed Two (HS2) has completed the civil engineering phase at the Long Itchington Wood Tunnel in Warwickshire, England, the first deep tunnel on the high-speed route to reach this ...

Credit: HS2. The UK’s High Speed Two (HS2) has completed the civil engineering phase at the Long Itchington Wood Tunnel in Warwickshire, England, the first deep tunnel on the high-speed route to reach ...

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the stage for the Chicago-based firm to submit the drug candidate for ...

The Company's ongoing RESOLVE trial is a Phase 1b/2a, multi-center, open-label, dose-escalation study that is evaluating EP-104GI across multiple patient cohorts by assessing key clinical ...

The Company's ongoing RESOLVE trial is a Phase 1b/2a, multi-center, open-label, dose-escalation study that is evaluating EP-104GI across multiple patient cohorts by assessing key clinical measurements ...